A Randomized, Double-Blind, Placebo-Controlled, Five Parallel Groups Efficacy and Safety Study of NS 2330 (Tesofensine) (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor Fluctuations
This study has been completed.
Study NCT00148512
Information provided by Boehringer Ingelheim Pharmaceuticals
First Received: September 7, 2005
Last Updated: January 12, 2007
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
